ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/18/2023 | 11.8% | Citigroup | $2.1 → $1.8 | Maintains | Buy |
| 08/07/2023 | 210.56% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/04/2023 | 24.22% | Chardan Capital | → $2 | Reiterates | Neutral → Neutral |
| 05/17/2023 | 179.5% | Cantor Fitzgerald | $5 → $4.5 | Maintains | Overweight |
| 05/17/2023 | 272.67% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 05/17/2023 | 210.56% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 03/30/2023 | 272.67% | JMP Securities | → $6 | Reiterates | → Market Outperform |
| 03/30/2023 | 210.56% | HC Wainwright & Co. | $1.5 → $5 | Maintains | Buy |
| 12/23/2022 | 210.56% | Raymond James | $2 → $5 | Maintains | Outperform |
| 12/22/2022 | 210.56% | Cantor Fitzgerald | $0.8 → $5 | Upgrades | Neutral → Overweight |
| 08/15/2022 | -6.83% | HC Wainwright & Co. | $2 → $1.5 | Maintains | Buy |
| 08/12/2022 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 08/12/2022 | 24.22% | Raymond James | → $2 | Upgrades | Market Perform → Outperform |
| 05/09/2022 | 24.22% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 05/06/2022 | 24.22% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 04/14/2022 | 55.28% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 04/14/2022 | 210.56% | JMP Securities | $8 → $5 | Maintains | Market Outperform |
| 02/14/2022 | 396.89% | Chardan Capital | $18 → $8 | Maintains | Buy |
| 02/14/2022 | 396.89% | JMP Securities | $29 → $8 | Maintains | Market Outperform |
| 02/14/2022 | 148.45% | HC Wainwright & Co. | $20 → $4 | Maintains | Buy |
| 02/14/2022 | — | Raymond James | Downgrades | Strong Buy → Market Perform | |
| 02/01/2022 | 1080.12% | Raymond James | → $19 | Initiates Coverage On | → Strong Buy |
| 08/09/2021 | 1018.01% | Chardan Capital | $20 → $18 | Maintains | Buy |
| 05/03/2021 | 1142.24% | Stifel | → $20 | Initiates Coverage On | → Buy |
| 08/11/2020 | 1142.24% | Chardan Capital | $25 → $20 | Maintains | Buy |
| 11/19/2019 | 1949.69% | Citigroup | $40 → $33 | Maintains | Buy |
| 11/14/2018 | 2384.47% | Cantor Fitzgerald | → $40 | Initiates Coverage On | → Overweight |
| 09/19/2018 | 2073.91% | Evercore ISI Group | → $35 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/18/2023 | 11.8% | 花旗集團 | $2.1→$1.8 | 維護 | 買 |
| 08/07/2023 | 210.56% | HC Wainwright公司 | →$5 | 重申 | 購買→購買 |
| 08/04/2023 | 24.22% | 查爾丹資本 | →$2 | 重申 | 中性→中性 |
| 2023年05月17日 | 179.5% | 康託·菲茨傑拉德 | $5→$4.5 | 維護 | 超重 |
| 2023年05月17日 | 272.67% | JMP證券 | →$6 | 重申 | 市場表現優於→市場表現 |
| 2023年05月17日 | 210.56% | HC Wainwright公司 | →$5 | 重申 | 購買→購買 |
| 03/30/2023 | 272.67% | JMP證券 | →$6 | 重申 | →市場跑贏大盤 |
| 03/30/2023 | 210.56% | HC Wainwright公司 | $1.5→$5 | 維護 | 買 |
| 2022年12月23日 | 210.56% | 雷蒙德·詹姆斯 | $2→$5 | 維護 | 跑贏大盤 |
| 2022年12月22日 | 210.56% | 康託·菲茨傑拉德 | $0.8→$5 | 升級 | 中性→超重 |
| 2022年08月15日 | -6.83% | HC Wainwright公司 | $2→$1.5 | 維護 | 買 |
| 2022年08月12日 | - | 查爾丹資本 | 評級下調 | 購買→中性 | |
| 2022年08月12日 | 24.22% | 雷蒙德·詹姆斯 | →$2 | 升級 | 市場表現優於→ |
| 05/09/2022 | 24.22% | HC Wainwright公司 | $4→$2 | 維護 | 買 |
| 05/06/2022 | 24.22% | 查爾丹資本 | $2.5→$2 | 維護 | 買 |
| 04/14/2022 | 55.28% | 查爾丹資本 | $8→$2.5 | 維護 | 買 |
| 04/14/2022 | 210.56% | JMP證券 | $8→$5 | 維護 | 市場表現強於大盤 |
| 02/14/2022 | 396.89% | 查爾丹資本 | $18→$8 | 維護 | 買 |
| 02/14/2022 | 396.89% | JMP證券 | $29→$8 | 維護 | 市場表現強於大盤 |
| 02/14/2022 | 148.45% | HC Wainwright公司 | $20→$4 | 維護 | 買 |
| 02/14/2022 | - | 雷蒙德·詹姆斯 | 評級下調 | 強勁的購買→市場表現 | |
| 02/01/2022 | 1080.12% | 雷蒙德·詹姆斯 | →$19 | 開始承保 | →強勢購買 |
| 08/09/2021 | 1018.01% | 查爾丹資本 | $20→$18 | 維護 | 買 |
| 05/03/2021 | 1142.24% | Stifel | →$20 | 開始承保 | →購買 |
| 2020年08月11日 | 1142.24% | 查爾丹資本 | $25→$20 | 維護 | 買 |
| 2019年11月19日 | 1949.69% | 花旗集團 | $40→$33 | 維護 | 買 |
| 2018年11月14日 | 2384.47% | 康託·菲茨傑拉德 | →$40 | 開始承保 | →超重 |
| 2018年09月19日 | 2073.91% | Evercore ISI集團 | →$35 | 開始承保 | →跑贏大盤 |
What is the target price for ProQR Therapeutics (PRQR)?
ProQR治療(PRQR)的目標價格是多少？
The latest price target for ProQR Therapeutics (NASDAQ: PRQR) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $1.80 expecting PRQR to rise to within 12 months (a possible 11.80% upside). 10 analyst firms have reported ratings in the last year.
花旗集團於2023年9月18日報道了ProQR治療公司(納斯達克：PRQR)的最新目標價。這家分析公司將目標價定為1.80美元，預計PRQR將在12個月內升至(可能上漲11.80%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for ProQR Therapeutics (PRQR)?
ProQR治療公司(PRQR)的最新分析師評級是什麼？
The latest analyst rating for ProQR Therapeutics (NASDAQ: PRQR) was provided by Citigroup, and ProQR Therapeutics maintained their buy rating.
花旗集團提供了對ProQR治療公司(納斯達克代碼：PRQR)的最新分析師評級，而ProQR治療公司維持其買入評級。
When is the next analyst rating going to be posted or updated for ProQR Therapeutics (PRQR)?
ProQR治療(PRQR)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與ProQR治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。ProQR治療公司的上一次評級是在2023年9月18日提交的，所以你應該預計下一次評級將在2024年9月18日左右提供。
Is the Analyst Rating ProQR Therapeutics (PRQR) correct?
分析師對ProQR Treeutics(PRQR)的評級正確嗎？
While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a maintained with a price target of $2.10 to $1.80. The current price ProQR Therapeutics (PRQR) is trading at is $1.61, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的ProQR治療(PRQR)評級保持不變，目標價在2.10美元至1.80美元之間。ProQR治療公司(PRQR)目前的交易價格為1.61美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。